Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO ® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results